% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Mulder:307560,
      author       = {R. L. Mulder and E. C. van Dalen and J. Teepen and M. M.
                      Hudson and L. S. Constine and S. Bhatia and W. Landier and
                      G. Levitt and W. H. Wallace and F. E. van Leeuwen and C.
                      Ronckers$^*$ and T. O. Henderson and C. S. Moskowitz and D.
                      N. Friedman and A. K. Ng and H. C. Jenkinson and C.
                      Demoor-Goldschmidt and D. Barnea and M. J. Ehrhardt and J.
                      W. van As and H. J. van der Pal and J. M. Yeh and R. Skinner
                      and L. C. M. Kremer and K. C. Oeffinger},
      title        = {{I}nternational {G}uideline {H}armonization {G}roup
                      {R}ecommendations for {B}reast {C}ancer {S}urveillance in
                      {C}hildhood, {A}dolescent, and {Y}oung {A}dult {C}ancer
                      {S}urvivors {A}fter {A}nthracyclines.},
      journal      = {JCO oncology practice},
      volume       = {nn},
      issn         = {2688-1527},
      address      = {Alexandria, Va.},
      publisher    = {American Society of Clinical Oncology},
      reportid     = {DKFZ-2026-00056},
      pages        = {nn},
      year         = {2026},
      note         = {ISSN 2688-1535 / epub},
      abstract     = {With new evidence emerging about breast cancer risk
                      following anthracycline chemotherapy, the International Late
                      Effects of Childhood Cancer Guideline Harmonization Group
                      updated the evidence and breast cancer surveillance
                      recommendations for female childhood, adolescent, and young
                      adult (CAYA) cancer survivors.The Grading of Recommendations
                      Assessment, Development, and Evaluation methodology was used
                      to incorporate new knowledge and refine breast cancer
                      surveillance recommendations. The guideline panel updated
                      the systematic literature review and revised recommendations
                      based on new evidence, clinical judgment, and assessments of
                      benefits and harms of surveillance, ensuring adaptability
                      across various health care systems.The literature update
                      revealed new findings on the effects of anthracyclines on
                      breast cancer risk in female CAYA cancer survivors.
                      Moderate-quality evidence shows no significant association
                      between doxorubicin doses <100 mg/m2 and breast cancer risk.
                      High-quality evidence indicates a statistically significant
                      but weak association between breast cancer risk and 100-199
                      mg/m2 doxorubicin (relative risk, <2) and a moderate breast
                      cancer risk (relative risk, 2-4) for those treated with
                      ≥200 mg/m2 in the absence of radiotherapy exposing breast
                      tissue (chest radiation). Routine breast cancer surveillance
                      after ≥200 mg/m2 doxorubicin in the absence of chest
                      radiation is reasonable from age 30 years onward or ≥8
                      years from exposure (whichever occurs last). Due to
                      inconclusive evidence, no recommendation could be formulated
                      for routine breast cancer surveillance after daunorubicin,
                      epirubicin, or idarubicin, in the absence of chest
                      radiation.The newly identified evidence on breast cancer
                      risk after anthracyclines supports changes in the 2019
                      recommendations regarding breast cancer surveillance for
                      survivors treated with ≥200 mg/m2 doxorubicin without
                      chest radiation.},
      subtyp        = {Review Article},
      cin          = {C190},
      ddc          = {610},
      cid          = {I:(DE-He78)C190-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41499731},
      doi          = {10.1200/OP-25-01017},
      url          = {https://inrepo02.dkfz.de/record/307560},
}